Novartis and Pfizer to Explore NASH Combinations
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 9 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2368 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an attempt to break into the non-alcoholic steatohepatitis (NASH) market, Novartis has partnered up with Pfizer to explore combination therapies for the disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018